Pregnancy in the time of Zika: Addressing barriers for developing vaccines and other measures for pregnant women

JAMA - Journal of the American Medical Association

Volumn 315, Issue 12, 2016, Pages 1227-1228

  Omer, Saad B ^a   Beigi, Richard H ^b  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ADVERSE OUTCOME; CHILD HEALTH CARE; DRUG SAFETY; EPIDEMIC; FIRST TRIMESTER PREGNANCY; HUMAN; NEWBORN INFECTION; NOTE; OBSTETRIC PROCEDURE; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; TERATOGENICITY; VACCINE PRODUCTION; VERTICAL TRANSMISSION; VIRUS INFECTION; DRUG LABELING; FEMALE; IMMUNOLOGY; LEGISLATION AND JURISPRUDENCE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; RESEARCH ETHICS; SAFETY; VIROLOGY; ZIKA VIRUS; ZIKA VIRUS INFECTION;

DRUG LABELING; ETHICS, RESEARCH; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANT WOMEN; SAFETY; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 84962260188     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.2237     Document Type: Note

References (9)

1. Shah S, Whittle A, Wilfond B, Gensler G, Wendler D. How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA. 2004;291(4):476-482.
2. Trannoy E. Will ethical and liability issues and public acceptance allow maternal immunization? Vaccine. 1998;16(14-15):1482-1485.
3. Paradiso PR. Maternal immunization: the influence of liability issues on vaccine development. Vaccine. 2001;20(SUPPL. 1):S73-S74.
4. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014;370(23):2211-2218.
5. Gruber MF. The US FDA pregnancy, lactation, and labeling rule: implications for maternal immunization. Vaccine. 2015;33(47):6499-6500.
6. Jackson LA, Campbell JD, Frey SE, et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA. 2015;314(3):237-246.
7. Fulton TR, Narayanan D, Bonhoeffer J, Ortiz JR, Lambach P, Omer SB. A systematic review of adverse events following immunization during pregnancy and the newborn period. Vaccine. 2015; 33(47):6453-6465.
8. Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009; 374(9707):2115-2122.
9. Ren Z, Zajicek A. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: what can the obstetric community learn from the pediatric experience? Semin Perinatol. 2015;39(7):530-531.